Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women
2005; American Diabetes Association; Volume: 28; Issue: 4 Linguagem: Inglês
10.2337/diacare.28.4.982
ISSN1935-5548
AutoresGraziano Di Cianni, Laura Volpe, Cristina Lencioni, Kyriazoula Chatzianagnostou, Ilaria Cuccuru, Alessandra Ghio, Luca Benzi, Stefano Del Prato,
Tópico(s)Pancreatic function and diabetes
ResumoThe long-acting analog glargine is a new insulin with 24-h persistence. This peculiar peakless action profile accounts for significant risk reduction for nocturnal hypoglycemia and a more stable daily plasma glucose profile (1,2). Only a few reports have described the use of insulin glargine during human pregnancy, so its use is not recommended at present. Animal studies have addressed the safety and efficacy of glargine during pregnancy, showing no direct effect on reproduction and embryo-fetal development (3 ) . Recently, Devlin et al. (4) and Holstein et al. (5) reported the use of insulin glargine in two type 1 diabetic women; both cases were free of any pregnancy complications and …
Referência(s)